91 related articles for article (PubMed ID: 22523841)
1. [In vitro synergisms among hydrazones, ajoeno and posaconazole against Cryptococcus spp].
Vivas J; Alvarado P; Visbal G; Alvarez-Aular A; Ruiz E; Ledezma E
Invest Clin; 2011 Dec; 52(4):312-22. PubMed ID: 22523841
[TBL] [Abstract][Full Text] [Related]
2. Müeller-Hinton methylene blue media as an alternative to RPMI 1640 for determining the susceptibility of Cryptococcus neoformans and Cryptococcus gattii to posaconazole with Etest.
Alvarado-Ramírez E; Torres-Rodríguez JM; Murciano F; Sellart M
Mycoses; 2010 Mar; 53(2):114-6. PubMed ID: 19863724
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Pfaller MA; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
[TBL] [Abstract][Full Text] [Related]
4. Antifungal activity of posaconazole against Candida spp. and non-Candida clinical yeasts isolates.
Carrillo-Muñoz AJ; Tur-Tur C; Hernández-Molina JM; Quindós G; Marcos-Arias C; Eraso E; Cárdenes D; Ortiz-Maestro O; Santos P; Estivill D; Guardia C; Giusiano G
Rev Esp Quimioter; 2010 Sep; 23(3):122-5. PubMed ID: 20844842
[TBL] [Abstract][Full Text] [Related]
5. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.
Espinel-Ingroff A
J Clin Microbiol; 2006 Oct; 44(10):3616-22. PubMed ID: 16943356
[TBL] [Abstract][Full Text] [Related]
6. Comparison of disc diffusion assay with the CLSI reference method (M27-A2) for testing in vitro posaconazole activity against common and uncommon yeasts.
Cantón E; Pemán J; Espinel-Ingroff A; Martín-Mazuelos E; Carrillo-Muñoz A; Martínez JP
J Antimicrob Chemother; 2008 Jan; 61(1):135-8. PubMed ID: 18033784
[TBL] [Abstract][Full Text] [Related]
7. In vitro susceptibility of Cryptococcus gattii clinical isolates.
Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.
Pfaller MA; Messer SA; Boyken L; Hollis RJ; Rice C; Tendolkar S; Diekema DJ
Diagn Microbiol Infect Dis; 2004 Mar; 48(3):201-5. PubMed ID: 15023430
[TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
10. In vitro antifungal synergy between amphiphilic aminoglycoside K20 and azoles against Candida species and Cryptococcus neoformans.
Shrestha SK; Grilley M; Anderson T; Dhiman C; Oblad J; Chang CW; Sorensen KN; Takemoto JY
Med Mycol; 2015 Nov; 53(8):837-44. PubMed ID: 26260746
[TBL] [Abstract][Full Text] [Related]
11. Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species.
Sóczó G; Kardos G; McNicholas PM; Balogh E; Gergely L; Varga I; Kelentey B; Majoros L
J Antimicrob Chemother; 2007 Nov; 60(5):1004-9. PubMed ID: 17875607
[TBL] [Abstract][Full Text] [Related]
12. [In vitro inhibitory effect of ajoene on Candida isolates recovered from vaginal discharges].
Carrero S; Romero H; Apitz-Castro R
Rev Iberoam Micol; 2009 Sep; 26(3):189-93. PubMed ID: 19635444
[TBL] [Abstract][Full Text] [Related]
13. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
15. Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp.
Sims CR; Paetznick VL; Rodriguez JR; Chen E; Ostrosky-Zeichner L
J Clin Microbiol; 2006 Jun; 44(6):2105-8. PubMed ID: 16757605
[TBL] [Abstract][Full Text] [Related]
16. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
[TBL] [Abstract][Full Text] [Related]
17. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.
Espinel-Ingroff A; Chowdhary A; Gonzalez GM; Guinea J; Hagen F; Meis JF; Thompson GR; Turnidge J
Antimicrob Agents Chemother; 2015 Jan; 59(1):666-8. PubMed ID: 25313209
[TBL] [Abstract][Full Text] [Related]
18. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
[TBL] [Abstract][Full Text] [Related]
19. Interactions of posaconazole and flucytosine against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Najvar LK; Bocanegra R; Caselli F; Di Cesare S; Giannini D; Di Francesco LF; Giacometti A; Carle F; Scalise G; Graybill JR
Antimicrob Agents Chemother; 2001 May; 45(5):1355-9. PubMed ID: 11302795
[TBL] [Abstract][Full Text] [Related]
20. Thiazole compounds with activity against Cryptococcus gattii and Cryptococcus neoformans in vitro.
Pereira de Sá N; Lino CI; Fonseca NC; Borelli BM; Ramos JP; Souza-Fagundes EM; Rosa CA; Santos DA; Barbosa de Oliveira R; Johann S
Eur J Med Chem; 2015 Sep; 102():233-42. PubMed ID: 26276437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
